Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 October 2019 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Human Settlements Conference
Attending the first National Student Conference for Human Settlement students were, from the left: Dr Anita Venter, Lecturer in the Centre for Development Support; Phelani Mkhize, master’s student in Urban and Regional Planning; Prof Maléne Campbell, Head of the Department of Urban and Regional Planning at the UFS; and Nhlakampho Mahlalela, also a master’s student in Urban and Regional Planning.

“This invitation by the University of the Free State (UFS) comes at a critical moment when we begin to roll up our sleeves in an attempt to transform the lives of our people, and in efforts to modernise our cities and towns to attain sustainable livelihoods.” This was the words of the MEC for Public Works, Infrastructure and Human Settlements, Tshidi Koloi, on attending the first National Student Conference for Human Settlement. 

“The urban population of the world has grown rapidly – from 751 million in 1950 to 8 billion in 2018. How do we plan for rapid urbanisation?” Koloi asked. 

“We turn to the academic world for continuous research in various fields related to the development of human settlements. The role of the university and of this department cannot be overestimated. Clearly, we need to forge partnerships where our department can benefit from ongoing research towards the improvement of its value chain and programmes. In return, government could offer bursaries and internship opportunities for students.”

Integrate communities

More than 130 students from the Nelson Mandela University, the UUniversity of KwaZulu-Natal, the University of the Witwatersrand, and the UFS attended the conference to gain a better understanding of the challenges, policies, and practices of human settlements. The conference also allowed students the opportunity to not only engage with key members of government, but also with each other and delegates from the private sector.

Head of the Department of Human Settlements, Tim Mokhesi, said his department’s objective with housing for the future is to integrate communities; not to separate them because they are poor. If we separate communities, our next struggle will be a class struggle. 

“South Africa is in a crisis in terms of human settlement. In the past years, there was an exponential growth in informal settlements – 300 to 3 000 (with 143 in the Free State); the housing budget shrank, and local authorities do not have the capacity to deal with informal settlements. Can the few of us make a sufficient and significant contribution? Seeing your commitment as students is what gives us hope for a better future for all,” Thomas Stewart, Lecturer in the UFS Department of Urban and Regional Planning, said. 

content photo 1
Attending the launch of the new Bachelor of Spatial Planning Honours with specialisation in Human Settlements were, from the left: Thomas
Stewart, Lecturer in the UFS Department of Urban and Re-gional Planning;  Tshidi Koloi,  MEC of Public Works, Infrastructure and
Human Settlements;  and Pura Mgolombane (Dean of Student Affairs at the UFS). (Photo: Leonie Bolleurs)


Innovative and inclusive re-housing

Students experienced two fieldtrips, one to the Hillside View Development Project, where the focus was on mixed housing. This project is part of the Mangaung Metro Municipality’s five-year integrated human settlements plan. According to developer Freddie Kenney, the project needs to be a development model for South Africa to change the picture of social housing. 

The second site visited was the Innovative Housing Building Project: Qala Phelang Tala, where peo-ple are trained to build their own houses. “It is a very easy process,” said Dr Anita Venter, Lecturer in the Centre for Development Support, who is lecturing Human Settlements Theory in the Department of Urban and Regional Planning. Since 2013, she was involved in the building of five houses. 

The latest building project at the Meraka Cultural Village in Roodewal, outside Bloemfontein, is a stu-dent-led project where they learn to develop a basic shelter suitable for survival in a future, post-natural, and climate-crisis world that will become between 2 and 4 degrees Celsius warmer within the next century. “It is important for people to build in climate-friendly ways,” Dr Venter said. 

She continues: “The project seeks to also renew, restore, and revitalise communities.” Sebabatso Mofama, who now helps with training, built this house similar to the one where she comes from in the Eastern Cape. “It is where I feel at home,” she said. 

The human aspect 

Dean of Student Affairs,Pura Mgolombane, touched on the human aspect of human settlements. “We first need to see the human in human settlements. ‘Yebo’, meaning I see you. See the human and develop quality houses.”

The event coincided with the launch of the new Bachelor of Spatial Planning Honours with specialisation in Human Settlements. The first two students graduated in April this year.
Content photo 2
Thapelo Chacha, master’s student in Urban and Regional Planning at the UFS, MEC Tshidi Koloi, and Sebabatso Mofama, mentor in the
Innovative Housing Building Project: Qala Phelang Tala. (Photo: Leonie Bolleurs) 





News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept